341 related articles for article (PubMed ID: 35463328)
1. Targeting ALK Rearrangements in NSCLC: Current State of the Art.
Peng L; Zhu L; Sun Y; Stebbing J; Selvaggi G; Zhang Y; Yu Z
Front Oncol; 2022; 12():863461. PubMed ID: 35463328
[TBL] [Abstract][Full Text] [Related]
2. How to select the best upfront therapy for metastatic disease? Focus on
Xia B; Nagasaka M; Zhu VW; Ou SI; Soo RA
Transl Lung Cancer Res; 2020 Dec; 9(6):2521-2534. PubMed ID: 33489815
[TBL] [Abstract][Full Text] [Related]
3. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
[TBL] [Abstract][Full Text] [Related]
4. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
5. Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer-a narrative review.
Chazan G; Solomon BJ
Transl Lung Cancer Res; 2023 Feb; 12(2):369-378. PubMed ID: 36895924
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
7. Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors.
Singh A; Chen H
Cancer Manag Res; 2020; 12():6615-6628. PubMed ID: 32821158
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer.
Wang WQ; Xu T; Zhang JJ; Wang Y; Wang Y; Zhang W; Zhu JG
J Thorac Dis; 2023 Apr; 15(4):1935-1947. PubMed ID: 37197536
[TBL] [Abstract][Full Text] [Related]
9. The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
Gristina V; La Mantia M; Iacono F; Galvano A; Russo A; Bazan V
Pharmaceuticals (Basel); 2020 Dec; 13(12):. PubMed ID: 33352844
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
Peng L; Lu D; Xia Y; Hong S; Selvaggi G; Stebbing J; Sun Y; Liang F
Front Oncol; 2021; 11():754768. PubMed ID: 34820326
[TBL] [Abstract][Full Text] [Related]
11. ALK Inhibitors in the Treatment of ALK Positive NSCLC.
Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
Front Oncol; 2018; 8():557. PubMed ID: 30687633
[No Abstract] [Full Text] [Related]
12. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
13. Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
Beardslee T; Lawson J
J Adv Pract Oncol; 2018; 9(1):94-101. PubMed ID: 30564472
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison.
Yu Y; Zhu F; Zhang W; Lu S
J Clin Med; 2022 May; 11(11):. PubMed ID: 35683354
[TBL] [Abstract][Full Text] [Related]
15. Treating ALK-positive non-small cell lung cancer.
Ziogas DC; Tsiara A; Tsironis G; Lykka M; Liontos M; Bamias A; Dimopoulos MA
Ann Transl Med; 2018 Apr; 6(8):141. PubMed ID: 29862230
[TBL] [Abstract][Full Text] [Related]
16. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
[TBL] [Abstract][Full Text] [Related]
17. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
[TBL] [Abstract][Full Text] [Related]
18. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC.
Yun KM; Bazhenova LA
Cancer Manag Res; 2022; 14():843-850. PubMed ID: 35250311
[TBL] [Abstract][Full Text] [Related]
19. Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice.
Passaro A; Lazzari C; Karachaliou N; Spitaleri G; Pochesci A; Catania C; Rosell R; de Marinis F
Onco Targets Ther; 2016; 9():6361-6376. PubMed ID: 27799783
[TBL] [Abstract][Full Text] [Related]
20. Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.
Karachaliou N; Fernandez Bruno M; Bracht JWP; Rosell R
Onco Targets Ther; 2019; 12():4567-4575. PubMed ID: 31354290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]